Evogene Ltd. (EVGN) 10-Year Financial Performance & Capital Metrics

EVGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutEvogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Show more

Revenue $9M +50.9%
EBITDA -$19M +19.1%
Net Income -$16M +31.0%
EPS (Diluted) -2.89 +44.7%
Gross Margin 39.81% +60.5%
EBITDA Margin -225.94% +46.4%
Operating Margin -255.36% +45.4%
Net Margin -193.69% +54.3%
ROE -75.75% -0.7%
ROIC -102.42% +3.9%
Debt/Equity 0.87 +116.3%
Interest Coverage -175.27 -13.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 62.4%
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 24.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-5.2%

5Y62.42%

3Y109.17%

TTM-26.18%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM88.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM88.78%

ROCE

10Y Avg-39.74%

5Y Avg-52.33%

3Y Avg-57.29%

Latest-66.54%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.13M	6.54M	3.38M	1.75M	753K	1.04M	930K	1.68M	5.64M	8.51M
Revenue Growth %	-0.23%	-0.41%	-0.48%	-0.48%	-0.57%	0.38%	-0.11%	0.8%	2.37%	0.51%
Cost of Goods Sold+	9.73M	7.32M	4.68M	3.31M	3.1M	3.3M	3M	3.45M	4.24M	5.12M
COGS % of Revenue	0.87%	1.12%	1.38%	1.9%	4.12%	3.17%	3.23%	2.06%	0.75%	0.6%
Gross Profit+	1.4M	-778K	-1.3M	-1.56M	-2.35M	-2.26M	-2.07M	-1.77M	1.4M	3.39M
Gross Margin %	0.13%	-0.12%	-0.38%	-0.9%	-3.12%	-2.17%	-2.23%	-1.06%	0.25%	0.4%
Gross Profit Growth %	-0.61%	-1.56%	-0.67%	-0.2%	-0.5%	0.04%	0.08%	0.14%	1.79%	1.42%
Operating Expenses+	19.32M	20.31M	20.48M	19.69M	20.39M	24.57M	29.42M	27.94M	27.79M	25.12M
OpEx % of Revenue	1.74%	3.11%	6.06%	11.27%	27.08%	23.63%	31.63%	16.68%	4.93%	2.95%
Selling, General & Admin	4.38M	3.89M	5.5M	5.6M	5.77M	7.97M	9.99M	10.41M	9.68M	10.87M
SG&A % of Revenue	0.39%	0.59%	1.63%	3.2%	7.66%	7.67%	10.74%	6.22%	1.72%	1.28%
Research & Development	14.94M	16.42M	14.99M	14.09M	14.62M	16.6M	19.43M	17.53M	18.11M	14.26M
R&D % of Revenue	1.34%	2.51%	4.43%	8.07%	19.42%	15.96%	20.89%	10.46%	3.21%	1.68%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-17.92M	-21.09M	-21.79M	-21.25M	-22.74M	-26.84M	-31.49M	-29.71M	-26.39M	-21.73M
Operating Margin %	-1.61%	-3.22%	-6.44%	-12.17%	-30.2%	-25.8%	-33.86%	-17.74%	-4.68%	-2.55%
Operating Income Growth %	-0.17%	-0.18%	-0.03%	0.02%	-0.07%	-0.18%	-0.17%	0.06%	0.11%	0.18%
EBITDA+	-15.49M	-18.81M	-19.64M	-19.23M	-19.97M	-24.11M	-29.26M	-27.14M	-23.78M	-19.23M
EBITDA Margin %	-1.39%	-2.88%	-5.81%	-11.01%	-26.52%	-23.18%	-31.46%	-16.2%	-4.22%	-2.26%
EBITDA Growth %	-0.19%	-0.21%	-0.04%	0.02%	-0.04%	-0.21%	-0.21%	0.07%	0.12%	0.19%
D&A (Non-Cash Add-back)	2.44M	2.28M	2.15M	2.02M	2.77M	2.73M	2.23M	2.58M	2.61M	2.5M
EBIT	-17.02M	-19.4M	-20.7M	-20.64M	-18.74M	-25.91M	-30.03M	-29.51M	-25.82M	-17.88M
Net Interest Income+	2.33M	2.25M	2M	1.27M	405K	-39K	-112K	-59K	1.08M	833K
Interest Income	2.53M	2.4M	2.13M	1.41M	759K	230K	291K	182K	1.25M	957K
Interest Expense	195K	155K	129K	141K	354K	269K	403K	241K	171K	124K
Other Income/Expense	708K	1.53M	958K	472K	3.65M	661K	1.06M	-39K	404K	3.69M
Pretax Income+	-17.21M	-19.56M	-20.83M	-20.78M	-19.09M	-26.17M	-30.43M	-29.75M	-25.99M	-18.05M
Pretax Margin %	-1.55%	-2.99%	-6.16%	-11.9%	-25.35%	-25.17%	-32.72%	-17.76%	-4.61%	-2.12%
Income Tax+	0	36K	11K	30K	24K	32K	13K	90K	-33K	9K
Effective Tax Rate %	1%	1%	1%	1%	0.95%	0.89%	0.91%	0.9%	0.92%	0.91%
Net Income+	-17.21M	-19.59M	-20.84M	-20.76M	-18.11M	-23.37M	-27.79M	-26.64M	-23.88M	-16.48M
Net Margin %	-1.55%	-3%	-6.16%	-11.88%	-24.05%	-22.48%	-29.88%	-15.9%	-4.23%	-1.94%
Net Income Growth %	-0.18%	-0.14%	-0.06%	0%	0.13%	-0.29%	-0.19%	0.04%	0.1%	0.31%
Net Income (Continuing)	-17.21M	-19.59M	-20.84M	-20.81M	-19.11M	-26.21M	-30.45M	-29.84M	-25.95M	-18.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	253K	10.07M	10.84M	9.77M	6.86M	16.63M	16.29M
EPS (Diluted)+	-0.68	-0.77	-0.81	-0.81	-0.70	-0.64	-0.68	-6.46	-5.23	-2.89
EPS Growth %	-0.17%	-0.13%	-0.05%	0%	0.14%	0.09%	-0.06%	-8.5%	0.19%	0.45%
EPS (Basic)	-0.68	-0.77	-0.81	-0.81	-0.70	-0.64	-0.68	-6.46	-5.23	-2.89
Diluted Shares Outstanding	25.31M	25.44M	25.73M	25.75M	25.75M	36.55M	41.01M	4.12M	4.57M	5.7M
Basic Shares Outstanding	25.31M	25.44M	25.73M	25.75M	25.75M	36.55M	41.01M	4.12M	4.57M	5.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.38M	89.49M	72.79M	55.49M	49.03M	51.82M	56.89M	37.75M	34.47M	21.59M
Cash & Short-Term Investments	100.63M	88.11M	71.75M	54.47M	46.88M	48.23M	53.87M	35.35M	31.06M	15.31M
Cash Only	10.22M	3.24M	3.44M	5.81M	34.75M	46.23M	32.33M	28.98M	20.77M	15.3M
Short-Term Investments	90.41M	84.88M	68.32M	48.66M	12.13M	2M	21.54M	6.38M	10.29M	10K
Accounts Receivable	3.52M	1.18M	813K	746K	1.21M	2.17M	1.17M	803K	804K	1.49M
Days Sales Outstanding	115.31	65.58	87.77	155.86	586.52	760.88	460.76	174.98	52.03	63.77
Inventory	0	0	0	0	0	0	92K	566K	76K	1.82M
Days Inventory Outstanding	-	-	-	-	-	-	11.19	59.9	6.54	129.6
Other Current Assets	47K	47K	47K	47K	47K	47K	77K	32K	0	1.3M
Total Non-Current Assets+	8.22M	6.5M	4.81M	3.21M	22.34M	20.09M	19.41M	18.38M	16.63M	19.58M
Property, Plant & Equipment	8.2M	6.48M	4.79M	3.19M	5.25M	3.94M	4.18M	4.07M	3.44M	4.25M
Fixed Asset Turnover	1.36x	1.01x	0.71x	0.55x	0.14x	0.26x	0.22x	0.41x	1.64x	2.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	17.07M	16.14M	15.21M	14.14M	13.17M	12.2M
Long-Term Investments	0	0	0	0	0	0	0	0	0	82K
Other Non-Current Assets	22K	13K	19K	19K	9K	9K	25K	74K	28K	3.05M
Total Assets+	112.59M	95.99M	77.6M	58.69M	71.36M	71.92M	76.3M	56.13M	51.1M	39.86M
Asset Turnover	0.10x	0.07x	0.04x	0.03x	0.01x	0.01x	0.01x	0.03x	0.11x	0.21x
Asset Growth %	-0.12%	-0.15%	-0.19%	-0.24%	0.22%	0.01%	0.06%	-0.26%	-0.09%	-0.22%
Total Current Liabilities+	5.64M	5.22M	4.66M	5.43M	5.75M	9.68M	6.88M	5.63M	6.94M	18.7M
Accounts Payable	1.77M	1.33M	1.11M	1.01M	1M	863K	1.46M	1.04M	1.78M	1.23M
Days Payables Outstanding	66.44	66.34	86.55	111.89	117.75	95.42	177.94	109.64	153.63	87.49
Short-Term Debt	0	0	0	0	0	0	0	0	0	10.37M
Deferred Revenue (Current)	819K	1000K	620K	1000K	423K	119K	264K	101K	750K	683K
Other Current Liabilities	0	0	0	0	0	4.14M	0	0	0	2.88M
Current Ratio	18.51x	17.13x	15.61x	10.22x	8.53x	5.36x	8.27x	6.71x	4.96x	1.15x
Quick Ratio	18.51x	17.13x	15.61x	10.22x	8.53x	5.36x	8.25x	6.61x	4.95x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	294.01	125.24	-95.05	105.88
Total Non-Current Liabilities+	3.2M	3.47M	3.56M	2.96M	5.4M	5.36M	6M	15.71M	15.47M	6.33M
Long-Term Debt	0	0	0	0	0	0	0	10.11M	10.37M	0
Capital Lease Obligations	0	0	0	0	2.08M	1.66M	1.7M	932K	285K	1.91M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	26K	31K	33K	31K	0	0	0	0	393K	90K
Total Liabilities	8.84M	8.7M	8.22M	8.39M	11.15M	15.03M	12.88M	21.34M	22.42M	25.03M
Total Debt+	0	0	0	0	2.97M	2.44M	2.67M	11.93M	11.51M	12.87M
Net Debt	-10.22M	-3.24M	-3.44M	-5.81M	-31.78M	-43.79M	-29.66M	-17.05M	-9.27M	-2.43M
Debt / Equity	-	-	-	-	0.05x	0.04x	0.04x	0.34x	0.40x	0.87x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-91.90x	-136.06x	-168.88x	-150.74x	-64.24x	-99.76x	-78.14x	-123.30x	-154.33x	-175.27x
Total Equity+	103.75M	87.29M	69.38M	50.31M	60.22M	56.88M	63.42M	34.79M	28.68M	14.84M
Equity Growth %	-0.11%	-0.16%	-0.21%	-0.27%	0.2%	-0.06%	0.11%	-0.45%	-0.18%	-0.48%
Book Value per Share	4.10	3.43	2.70	1.95	2.34	1.56	1.55	8.44	6.28	2.60
Total Shareholders' Equity	103.75M	87.29M	69.38M	50.05M	50.14M	46.05M	53.65M	27.93M	12.05M	-1.45M
Common Stock	140K	141K	142K	142K	142K	200K	234K	235K	286K	363K
Retained Earnings	-76.6M	-96.19M	-117.03M	-137.79M	-155.9M	-179.28M	-207.07M	-233.71M	-257.59M	-274.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	183.34M	372.54M	187.7M	205.9M	225.12M	260.49M	261.4M	269.35M	272.26M
Minority Interest	0	0	0	253K	10.07M	10.84M	9.77M	6.86M	16.63M	16.29M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.41M	-11.69M	-15.93M	-15.16M	-17.36M	-19.51M	-24.84M	-23.68M	-21.58M	-19.7M
Operating CF Margin %	-1.11%	-1.79%	-4.71%	-8.68%	-23.06%	-18.76%	-26.71%	-14.14%	-3.83%	-2.31%
Operating CF Growth %	-0.39%	0.06%	-0.36%	0.05%	-0.15%	-0.12%	-0.27%	0.05%	0.09%	0.09%
Net Income	-17.21M	-19.59M	-20.84M	-20.81M	-19.11M	-26.21M	-30.45M	-29.84M	-25.95M	-18.05M
Depreciation & Amortization	2.43M	2.28M	2.15M	2.02M	2.77M	2.73M	2.23M	2.58M	2.61M	2.5M
Stock-Based Compensation	4.37M	2.94M	2.24M	1.73M	1.58M	4.1M	2.61M	1.19M	1.88M	1.79M
Deferred Taxes	2.69M	36K	11K	30K	24K	13K	13K	90K	-33K	9K
Other Non-Cash Items	-845K	705K	705K	2.03M	-1.62M	1.28M	-906K	3.08M	321K	-2.64M
Working Capital Changes	-3.84M	1.94M	-196K	-161K	-997K	-1.43M	1.66M	-771K	-400K	-3.31M
Change in Receivables	-1.49M	2.51M	37K	-28K	88K	-150K	-59K	-67K	-1.45M	191K
Change in Inventory	-1.22M	-279K	351K	146K	-895K	-912K	-92K	-474K	490K	-1.74M
Change in Payables	-68K	-215K	-86K	-114K	-122K	-29K	625K	-469K	742K	-596K
Cash from Investing+	17.39M	4.03M	15.24M	17.35M	37.14M	9.41M	-20.44M	13.27M	-4.54M	9.62M
Capital Expenditures	-2M	-808K	-590K	-374K	-900K	-682K	-724K	-1.17M	-785K	-626K
CapEx % of Revenue	0.18%	0.12%	0.17%	0.21%	1.2%	0.66%	0.78%	0.7%	0.14%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	953K	5.47M	4.76M	0	-10M	0	0	0	26K	58K
Cash from Financing+	45K	655K	814K	297K	9M	20.37M	30.28M	9.34M	18.15M	4.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	45K	655K	814K	297K	-97K	2.35M	1.27M	125K	10.54M	5.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.41M	-12.5M	-16.52M	-15.54M	-18.26M	-20.2M	-25.56M	-24.85M	-22.36M	-20.33M
FCF Margin %	-1.29%	-1.91%	-4.89%	-8.89%	-24.25%	-19.42%	-27.49%	-14.84%	-3.96%	-2.39%
FCF Growth %	-0.16%	0.13%	-0.32%	0.06%	-0.18%	-0.11%	-0.27%	0.03%	0.1%	0.09%
FCF per Share	-0.57	-0.49	-0.64	-0.60	-0.71	-0.55	-0.62	-6.03	-4.89	-3.57
FCF Conversion (FCF/Net Income)	0.72x	0.60x	0.76x	0.73x	0.96x	0.83x	0.89x	0.89x	0.90x	1.20x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-15.66%	-20.51%	-26.6%	-34.69%	-32.78%	-39.92%	-46.21%	-54.25%	-75.24%	-75.75%
Return on Invested Capital (ROIC)	-13.15%	-17.81%	-21.79%	-28.87%	-46.77%	-96.92%	-100.81%	-86.54%	-106.53%	-102.42%
Gross Margin	12.57%	-11.9%	-38.45%	-89.52%	-312.08%	-217.4%	-222.69%	-105.91%	24.8%	39.81%
Net Margin	-154.67%	-299.57%	-616.33%	-1188.21%	-2405.31%	-2247.5%	-2988.49%	-1590.33%	-423.39%	-193.69%
Debt / Equity	-	-	-	-	0.05x	0.04x	0.04x	0.34x	0.40x	0.87x
Interest Coverage	-91.90x	-136.06x	-168.88x	-150.74x	-64.24x	-99.76x	-78.14x	-123.30x	-154.33x	-175.27x
FCF Conversion	0.72x	0.60x	0.76x	0.73x	0.96x	0.83x	0.89x	0.89x	0.90x	1.20x
Revenue Growth	-23.31%	-41.23%	-48.3%	-48.33%	-56.9%	38.11%	-10.58%	80.11%	236.72%	50.9%

Frequently Asked Questions

Growth & Financials

Evogene Ltd. (EVGN) reported $5.3M in revenue for fiscal year 2024. This represents a 69% decrease from $17.1M in 2012.

Evogene Ltd. (EVGN) grew revenue by 50.9% over the past year. This is strong growth.

Evogene Ltd. (EVGN) reported a net loss of $2.7M for fiscal year 2024.

Dividend & Returns

Evogene Ltd. (EVGN) has a return on equity (ROE) of -75.8%. Negative ROE indicates the company is unprofitable.

Evogene Ltd. (EVGN) had negative free cash flow of $16.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Evogene Ltd. (EVGN) 10-Year Financial Performance & Capital Metrics

EVGN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $9M +50.9%
EBITDA -$19M +19.1%
Net Income -$16M +31.0%
EPS (Diluted) -2.89 +44.7%
Gross Margin 39.81% +60.5%
EBITDA Margin -225.94% +46.4%
Operating Margin -255.36% +45.4%
Net Margin -193.69% +54.3%
ROE -75.75% -0.7%
ROIC -102.42% +3.9%
Debt/Equity 0.87 +116.3%
Interest Coverage -175.27 -13.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 62.4%
✓Trading at only 0.4x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 20 (bottom 20%)
✗Shares diluted 24.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-5.2%

5Y62.42%

3Y109.17%

TTM-26.18%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM88.31%

EPS CAGR

10Y-

5Y-

3Y-

TTM88.78%

ROCE

10Y Avg-39.74%

5Y Avg-52.33%

3Y Avg-57.29%

Latest-66.54%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	11.13M	6.54M	3.38M	1.75M	753K	1.04M	930K	1.68M	5.64M	8.51M
Revenue Growth %	-0.23%	-0.41%	-0.48%	-0.48%	-0.57%	0.38%	-0.11%	0.8%	2.37%	0.51%
Cost of Goods Sold+	9.73M	7.32M	4.68M	3.31M	3.1M	3.3M	3M	3.45M	4.24M	5.12M
COGS % of Revenue	0.87%	1.12%	1.38%	1.9%	4.12%	3.17%	3.23%	2.06%	0.75%	0.6%
Gross Profit+	1.4M	-778K	-1.3M	-1.56M	-2.35M	-2.26M	-2.07M	-1.77M	1.4M	3.39M
Gross Margin %	0.13%	-0.12%	-0.38%	-0.9%	-3.12%	-2.17%	-2.23%	-1.06%	0.25%	0.4%
Gross Profit Growth %	-0.61%	-1.56%	-0.67%	-0.2%	-0.5%	0.04%	0.08%	0.14%	1.79%	1.42%
Operating Expenses+	19.32M	20.31M	20.48M	19.69M	20.39M	24.57M	29.42M	27.94M	27.79M	25.12M
OpEx % of Revenue	1.74%	3.11%	6.06%	11.27%	27.08%	23.63%	31.63%	16.68%	4.93%	2.95%
Selling, General & Admin	4.38M	3.89M	5.5M	5.6M	5.77M	7.97M	9.99M	10.41M	9.68M	10.87M
SG&A % of Revenue	0.39%	0.59%	1.63%	3.2%	7.66%	7.67%	10.74%	6.22%	1.72%	1.28%
Research & Development	14.94M	16.42M	14.99M	14.09M	14.62M	16.6M	19.43M	17.53M	18.11M	14.26M
R&D % of Revenue	1.34%	2.51%	4.43%	8.07%	19.42%	15.96%	20.89%	10.46%	3.21%	1.68%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-17.92M	-21.09M	-21.79M	-21.25M	-22.74M	-26.84M	-31.49M	-29.71M	-26.39M	-21.73M
Operating Margin %	-1.61%	-3.22%	-6.44%	-12.17%	-30.2%	-25.8%	-33.86%	-17.74%	-4.68%	-2.55%
Operating Income Growth %	-0.17%	-0.18%	-0.03%	0.02%	-0.07%	-0.18%	-0.17%	0.06%	0.11%	0.18%
EBITDA+	-15.49M	-18.81M	-19.64M	-19.23M	-19.97M	-24.11M	-29.26M	-27.14M	-23.78M	-19.23M
EBITDA Margin %	-1.39%	-2.88%	-5.81%	-11.01%	-26.52%	-23.18%	-31.46%	-16.2%	-4.22%	-2.26%
EBITDA Growth %	-0.19%	-0.21%	-0.04%	0.02%	-0.04%	-0.21%	-0.21%	0.07%	0.12%	0.19%
D&A (Non-Cash Add-back)	2.44M	2.28M	2.15M	2.02M	2.77M	2.73M	2.23M	2.58M	2.61M	2.5M
EBIT	-17.02M	-19.4M	-20.7M	-20.64M	-18.74M	-25.91M	-30.03M	-29.51M	-25.82M	-17.88M
Net Interest Income+	2.33M	2.25M	2M	1.27M	405K	-39K	-112K	-59K	1.08M	833K
Interest Income	2.53M	2.4M	2.13M	1.41M	759K	230K	291K	182K	1.25M	957K
Interest Expense	195K	155K	129K	141K	354K	269K	403K	241K	171K	124K
Other Income/Expense	708K	1.53M	958K	472K	3.65M	661K	1.06M	-39K	404K	3.69M
Pretax Income+	-17.21M	-19.56M	-20.83M	-20.78M	-19.09M	-26.17M	-30.43M	-29.75M	-25.99M	-18.05M
Pretax Margin %	-1.55%	-2.99%	-6.16%	-11.9%	-25.35%	-25.17%	-32.72%	-17.76%	-4.61%	-2.12%
Income Tax+	0	36K	11K	30K	24K	32K	13K	90K	-33K	9K
Effective Tax Rate %	1%	1%	1%	1%	0.95%	0.89%	0.91%	0.9%	0.92%	0.91%
Net Income+	-17.21M	-19.59M	-20.84M	-20.76M	-18.11M	-23.37M	-27.79M	-26.64M	-23.88M	-16.48M
Net Margin %	-1.55%	-3%	-6.16%	-11.88%	-24.05%	-22.48%	-29.88%	-15.9%	-4.23%	-1.94%
Net Income Growth %	-0.18%	-0.14%	-0.06%	0%	0.13%	-0.29%	-0.19%	0.04%	0.1%	0.31%
Net Income (Continuing)	-17.21M	-19.59M	-20.84M	-20.81M	-19.11M	-26.21M	-30.45M	-29.84M	-25.95M	-18.05M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	253K	10.07M	10.84M	9.77M	6.86M	16.63M	16.29M
EPS (Diluted)+	-0.68	-0.77	-0.81	-0.81	-0.70	-0.64	-0.68	-6.46	-5.23	-2.89
EPS Growth %	-0.17%	-0.13%	-0.05%	0%	0.14%	0.09%	-0.06%	-8.5%	0.19%	0.45%
EPS (Basic)	-0.68	-0.77	-0.81	-0.81	-0.70	-0.64	-0.68	-6.46	-5.23	-2.89
Diluted Shares Outstanding	25.31M	25.44M	25.73M	25.75M	25.75M	36.55M	41.01M	4.12M	4.57M	5.7M
Basic Shares Outstanding	25.31M	25.44M	25.73M	25.75M	25.75M	36.55M	41.01M	4.12M	4.57M	5.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	104.38M	89.49M	72.79M	55.49M	49.03M	51.82M	56.89M	37.75M	34.47M	21.59M
Cash & Short-Term Investments	100.63M	88.11M	71.75M	54.47M	46.88M	48.23M	53.87M	35.35M	31.06M	15.31M
Cash Only	10.22M	3.24M	3.44M	5.81M	34.75M	46.23M	32.33M	28.98M	20.77M	15.3M
Short-Term Investments	90.41M	84.88M	68.32M	48.66M	12.13M	2M	21.54M	6.38M	10.29M	10K
Accounts Receivable	3.52M	1.18M	813K	746K	1.21M	2.17M	1.17M	803K	804K	1.49M
Days Sales Outstanding	115.31	65.58	87.77	155.86	586.52	760.88	460.76	174.98	52.03	63.77
Inventory	0	0	0	0	0	0	92K	566K	76K	1.82M
Days Inventory Outstanding	-	-	-	-	-	-	11.19	59.9	6.54	129.6
Other Current Assets	47K	47K	47K	47K	47K	47K	77K	32K	0	1.3M
Total Non-Current Assets+	8.22M	6.5M	4.81M	3.21M	22.34M	20.09M	19.41M	18.38M	16.63M	19.58M
Property, Plant & Equipment	8.2M	6.48M	4.79M	3.19M	5.25M	3.94M	4.18M	4.07M	3.44M	4.25M
Fixed Asset Turnover	1.36x	1.01x	0.71x	0.55x	0.14x	0.26x	0.22x	0.41x	1.64x	2.00x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	17.07M	16.14M	15.21M	14.14M	13.17M	12.2M
Long-Term Investments	0	0	0	0	0	0	0	0	0	82K
Other Non-Current Assets	22K	13K	19K	19K	9K	9K	25K	74K	28K	3.05M
Total Assets+	112.59M	95.99M	77.6M	58.69M	71.36M	71.92M	76.3M	56.13M	51.1M	39.86M
Asset Turnover	0.10x	0.07x	0.04x	0.03x	0.01x	0.01x	0.01x	0.03x	0.11x	0.21x
Asset Growth %	-0.12%	-0.15%	-0.19%	-0.24%	0.22%	0.01%	0.06%	-0.26%	-0.09%	-0.22%
Total Current Liabilities+	5.64M	5.22M	4.66M	5.43M	5.75M	9.68M	6.88M	5.63M	6.94M	18.7M
Accounts Payable	1.77M	1.33M	1.11M	1.01M	1M	863K	1.46M	1.04M	1.78M	1.23M
Days Payables Outstanding	66.44	66.34	86.55	111.89	117.75	95.42	177.94	109.64	153.63	87.49
Short-Term Debt	0	0	0	0	0	0	0	0	0	10.37M
Deferred Revenue (Current)	819K	1000K	620K	1000K	423K	119K	264K	101K	750K	683K
Other Current Liabilities	0	0	0	0	0	4.14M	0	0	0	2.88M
Current Ratio	18.51x	17.13x	15.61x	10.22x	8.53x	5.36x	8.27x	6.71x	4.96x	1.15x
Quick Ratio	18.51x	17.13x	15.61x	10.22x	8.53x	5.36x	8.25x	6.61x	4.95x	1.06x
Cash Conversion Cycle	-	-	-	-	-	-	294.01	125.24	-95.05	105.88
Total Non-Current Liabilities+	3.2M	3.47M	3.56M	2.96M	5.4M	5.36M	6M	15.71M	15.47M	6.33M
Long-Term Debt	0	0	0	0	0	0	0	10.11M	10.37M	0
Capital Lease Obligations	0	0	0	0	2.08M	1.66M	1.7M	932K	285K	1.91M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	26K	31K	33K	31K	0	0	0	0	393K	90K
Total Liabilities	8.84M	8.7M	8.22M	8.39M	11.15M	15.03M	12.88M	21.34M	22.42M	25.03M
Total Debt+	0	0	0	0	2.97M	2.44M	2.67M	11.93M	11.51M	12.87M
Net Debt	-10.22M	-3.24M	-3.44M	-5.81M	-31.78M	-43.79M	-29.66M	-17.05M	-9.27M	-2.43M
Debt / Equity	-	-	-	-	0.05x	0.04x	0.04x	0.34x	0.40x	0.87x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-91.90x	-136.06x	-168.88x	-150.74x	-64.24x	-99.76x	-78.14x	-123.30x	-154.33x	-175.27x
Total Equity+	103.75M	87.29M	69.38M	50.31M	60.22M	56.88M	63.42M	34.79M	28.68M	14.84M
Equity Growth %	-0.11%	-0.16%	-0.21%	-0.27%	0.2%	-0.06%	0.11%	-0.45%	-0.18%	-0.48%
Book Value per Share	4.10	3.43	2.70	1.95	2.34	1.56	1.55	8.44	6.28	2.60
Total Shareholders' Equity	103.75M	87.29M	69.38M	50.05M	50.14M	46.05M	53.65M	27.93M	12.05M	-1.45M
Common Stock	140K	141K	142K	142K	142K	200K	234K	235K	286K	363K
Retained Earnings	-76.6M	-96.19M	-117.03M	-137.79M	-155.9M	-179.28M	-207.07M	-233.71M	-257.59M	-274.07M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	183.34M	372.54M	187.7M	205.9M	225.12M	260.49M	261.4M	269.35M	272.26M
Minority Interest	0	0	0	253K	10.07M	10.84M	9.77M	6.86M	16.63M	16.29M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.41M	-11.69M	-15.93M	-15.16M	-17.36M	-19.51M	-24.84M	-23.68M	-21.58M	-19.7M
Operating CF Margin %	-1.11%	-1.79%	-4.71%	-8.68%	-23.06%	-18.76%	-26.71%	-14.14%	-3.83%	-2.31%
Operating CF Growth %	-0.39%	0.06%	-0.36%	0.05%	-0.15%	-0.12%	-0.27%	0.05%	0.09%	0.09%
Net Income	-17.21M	-19.59M	-20.84M	-20.81M	-19.11M	-26.21M	-30.45M	-29.84M	-25.95M	-18.05M
Depreciation & Amortization	2.43M	2.28M	2.15M	2.02M	2.77M	2.73M	2.23M	2.58M	2.61M	2.5M
Stock-Based Compensation	4.37M	2.94M	2.24M	1.73M	1.58M	4.1M	2.61M	1.19M	1.88M	1.79M
Deferred Taxes	2.69M	36K	11K	30K	24K	13K	13K	90K	-33K	9K
Other Non-Cash Items	-845K	705K	705K	2.03M	-1.62M	1.28M	-906K	3.08M	321K	-2.64M
Working Capital Changes	-3.84M	1.94M	-196K	-161K	-997K	-1.43M	1.66M	-771K	-400K	-3.31M
Change in Receivables	-1.49M	2.51M	37K	-28K	88K	-150K	-59K	-67K	-1.45M	191K
Change in Inventory	-1.22M	-279K	351K	146K	-895K	-912K	-92K	-474K	490K	-1.74M
Change in Payables	-68K	-215K	-86K	-114K	-122K	-29K	625K	-469K	742K	-596K
Cash from Investing+	17.39M	4.03M	15.24M	17.35M	37.14M	9.41M	-20.44M	13.27M	-4.54M	9.62M
Capital Expenditures	-2M	-808K	-590K	-374K	-900K	-682K	-724K	-1.17M	-785K	-626K
CapEx % of Revenue	0.18%	0.12%	0.17%	0.21%	1.2%	0.66%	0.78%	0.7%	0.14%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	953K	5.47M	4.76M	0	-10M	0	0	0	26K	58K
Cash from Financing+	45K	655K	814K	297K	9M	20.37M	30.28M	9.34M	18.15M	4.66M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	45K	655K	814K	297K	-97K	2.35M	1.27M	125K	10.54M	5.43M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-14.41M	-12.5M	-16.52M	-15.54M	-18.26M	-20.2M	-25.56M	-24.85M	-22.36M	-20.33M
FCF Margin %	-1.29%	-1.91%	-4.89%	-8.89%	-24.25%	-19.42%	-27.49%	-14.84%	-3.96%	-2.39%
FCF Growth %	-0.16%	0.13%	-0.32%	0.06%	-0.18%	-0.11%	-0.27%	0.03%	0.1%	0.09%
FCF per Share	-0.57	-0.49	-0.64	-0.60	-0.71	-0.55	-0.62	-6.03	-4.89	-3.57
FCF Conversion (FCF/Net Income)	0.72x	0.60x	0.76x	0.73x	0.96x	0.83x	0.89x	0.89x	0.90x	1.20x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-15.66%	-20.51%	-26.6%	-34.69%	-32.78%	-39.92%	-46.21%	-54.25%	-75.24%	-75.75%
Return on Invested Capital (ROIC)	-13.15%	-17.81%	-21.79%	-28.87%	-46.77%	-96.92%	-100.81%	-86.54%	-106.53%	-102.42%
Gross Margin	12.57%	-11.9%	-38.45%	-89.52%	-312.08%	-217.4%	-222.69%	-105.91%	24.8%	39.81%
Net Margin	-154.67%	-299.57%	-616.33%	-1188.21%	-2405.31%	-2247.5%	-2988.49%	-1590.33%	-423.39%	-193.69%
Debt / Equity	-	-	-	-	0.05x	0.04x	0.04x	0.34x	0.40x	0.87x
Interest Coverage	-91.90x	-136.06x	-168.88x	-150.74x	-64.24x	-99.76x	-78.14x	-123.30x	-154.33x	-175.27x
FCF Conversion	0.72x	0.60x	0.76x	0.73x	0.96x	0.83x	0.89x	0.89x	0.90x	1.20x
Revenue Growth	-23.31%	-41.23%	-48.3%	-48.33%	-56.9%	38.11%	-10.58%	80.11%	236.72%	50.9%

Frequently Asked Questions

Growth & Financials

Evogene Ltd. (EVGN) reported $5.3M in revenue for fiscal year 2024. This represents a 69% decrease from $17.1M in 2012.

Evogene Ltd. (EVGN) grew revenue by 50.9% over the past year. This is strong growth.

Evogene Ltd. (EVGN) reported a net loss of $2.7M for fiscal year 2024.

Dividend & Returns

Evogene Ltd. (EVGN) has a return on equity (ROE) of -75.8%. Negative ROE indicates the company is unprofitable.

Evogene Ltd. (EVGN) had negative free cash flow of $16.9M in fiscal year 2024, likely due to heavy capital investments.